Vavricka John 4
4 · Atea Pharmaceuticals, Inc. · Filed Nov 3, 2020
Insider Transaction Report
Form 4
Vavricka John
Chief Commercial Officer
Transactions
- Conversion
Common Stock
2020-11-03+82,508→ 82,508 total(indirect: By Trust) - Conversion
Series B Convertible Preferred Stock
2020-11-03−82,508→ 0 total(indirect: By Trust)→ Common Stock (82,508 underlying)
Footnotes (1)
- [F1]The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.